[1] Bernstein CN, Fried M, Krabshuis JH, et al. 2010年世界胃肠病学组织关于炎症性肠病诊断和治疗的实践指南[J]. 胃肠病学,2010,15(9):548-558.
[2] 郭小芹. IL-17/IL-17R通路在炎症性肠病中的免疫调节机制研究[D].北京:中国人民解放军军事医学科学院,2013.
[3] Rammeart DC, Canling SR. Inflammatory bowel disease: cause and immunobiology[J]. Lancet,2007,369(9673):1627-1640.
[4] Parkes M. The genetics universe of Crohn's disease and ulcerative colitis[J]. Dig Dis,2012,30(Suppl 1):78-81.
[5] Ye BD, Yang SK, Cho YK, et al. Clinical features and long-term prognosis of Crohn's disease in Korea[J]. Scand J Gastroenterol,2010,45(10):1178-1185.
[6] 牛润章,张兰兰,司依馨. 炎症性肠病的病因及诊治研究进展[J]. 实用医药杂志,2014,31(5):461-463.
[7] 欧阳钦. 炎症性肠病的病因和发病机制[J]. 实用医学杂志,2003,19(5):448-449.
[8] Maesla S, Hsu LC, Lin H, et al. Nod-mutation in Crohn's disease potenliales NF-kappaB activity and IL-beta processing[J]. Science,2005,307(5710):734-738.
[9] 肖 梅,吴正祥. 炎症性肠病的病因研究进展[J]. 安徽医药,2005,9(12):886-889.
[10] Campieri M, Gionchetti P. Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeatic alternative[J]. Gastroenterology,1999,116(5):1246-1249.
[11] 欧阳钦. 炎症性肠病发病机制与治疗研究进展[J]. 中国处方药,2004,23(4):15-19.
[12] Rath HC, Schultz M, Freitag R, et al. Different subsets of enteric bacteria induced and perpetuate experimental colitis in rats and mice[J]. Infect Immune,2001,69(4):2277-2285.
[13] 郭 璟. 4-氨基水杨酸抗炎性肠病衍生物的合成研究[D]. 山西:山西医科大学,2004.
[14] 黄雪彪. 炎症性肠病的药物治疗[J]. 临床药物治疗杂志,2003,1(4):27-32.
[15] Camma C, Giunta M, Rosselli M, et al. Mesalamine in the maintenance of Crohn's disease: a meta-analysis adjusted for confounding variables[J]. Gastroenterology,1997,113(5):1465-1473.
[16] Campieri M, Lanfranchi GA, Bertoni F, et al. A double-blind clinical trial to compare the effects of 4-aminosalicylic acid to 5-aminosalicylic acid in topical treatment of ulcerative colitis[J].Digestion,1984,29(4):204-208.
[17] 靳宝芬. 4-氨基水杨酸和5-氨基水杨酸抗炎作用及作用机制研究[D].山西:山西医科大学,2014.
[18] 蒋蔚茹. 炎症性肠病的认识与治疗进展[J]. 上海医药,2010,31(5):207-210.
[19] 刘 凡. 炎症性肠病药物治疗现状与进展[J]. 沈阳医学院学报,2006,8(4):241-242.
[20] Hindorf U, Lindqvist M, Hildebrand H, et al. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease[J]. Aliment Pharmacol Ther, 2006,24(2):331-342.
[21] Gao X, Zhang FB, Ding L, et al. The potential influence of 5-aminosalicylic acid on the induction of myelotoxicity during thiopurine in inflammatory bowel disease patients[J]. Eur J Gastroenterol Hepatol,2012,24(8):958-964.
[22] Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma[J]. Gastroenterol,2000,118(6):1018.
[23] Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopu-rine, mesalamine, or placebo: a 2-year trial[J]. Gastroenterology, 2004,127(3):723-729.
[24] Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease[J]. Gastroenterology,2006,130(3):935-939.
[25] Feagan G, John M. Low-Dose Cyclosporine for the Treatment of Crohn's Disease[J]. Med, 1994,330(26):1846-1851.
[26] Cheifetz AS, Stern J, Garud S, et al. Cyclosporine is safe and effective in patients with severe ulcerative colitis[J]. Clin Gastroenterol,2011,45(2):107-112.
[27] 崔 静. 炎症性肠病发病机制和治疗方面某些进展[D].郑州:郑州大学,2004.
[28] 王俊珊,刘占举. 炎症性肠病的诊断和药物治疗相关指南解读[J]. 世界临床药物, 2005,36(12):809-813.
[29] 黄 瑛,王玉环. 儿童炎症性肠病的药物治疗[J]. 世界临床药物,2009,30(8):459-464.
[30] 李世荣. 生物靶向药物在炎症性肠病中的应用现状[J]. 中国新药杂志,2010,19(19):1750-1757.
[31] 杨志红,邓彤斌,王梦明,等. 炎症性肠病的病因学和药物治疗研究进展[J]. 中国药师, 2013,16(6): 905-907.
[32] 高树娟,施瑞华. 炎症性肠病治疗的新进展[J]. 世界华人消化杂志,2012,36:3742-3747.
[33] Papadakis KA. Safety and efficacy of ada limumab in Crohn's disease patients with an attenuated response to infliximab[J]. Gastroenterology,2011,100(1):75-79.
[34] Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease[J]. Aliment Pharmacol Ther,2010,132(1):1296-1309.